Association of Urine Galectin-3 With Cardiorenal Outcomes in Patients With Heart Failure.

BACKGROUND AND OBJECTIVES

Approaches to distinguishing pathological cardiorenal dysfunction in heart failure (HF) from functional/hemodynamically mediated changes in serum creatinine are needed. We investigated urine galectin-3 as a candidate biomarker of renal fibrosis and a prognostic indicator of cardiorenal dysfunction phenotypes.

METHODS

We measured urine galectin-3 in 2 contemporary HF cohorts: the Yale Transitional Care Clinic (YTCC) cohort (n = 132) and the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial (n = 434). We assessed the association of urine galectin-3 with all-cause mortality in both cohorts and the association with an established marker of renal tissue fibrosis, urinary amino-terminal propeptide of type III procollagen (PIIINP) in TOPCAT.

RESULTS

In the YTCC cohort, there was significant effect modification between higher urine galectin-3 and lower estimated glomerular filtration rates (eGFRs) (P

CONCLUSIONS

Urine galectin-3 levels correlated with an established biomarker of renal fibrosis in 2 cohorts and was able to differentiate high- vs low-risk phenotypes of chronic kidney disease in HF. These proof-of-concept results indicate that additional biomarker research to differentiate cardiorenal phenotypes is warranted.

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Disclosures JMT reports grants and/or personal fees from 3ive labs, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Astra Zeneca, Novartis, Cardionomic, MagentaMed, Reprieve, FIRE1,W.L. Gore, Sanofi, Sequana Medical, Otsuka, Abbott, Merck, Windtree Therapeutics, Lexicon Pharmaceuticals, Precardia, Relypsa, Regeneron, BD, Edwards Life Sciences, and Lilly; he has a patent for treatment of diuretic resistance issued to Yale and Corvidia Therapeutics, a patent for methods of measuring renalase issued to Yale, and a patent for treatment of diuretic resistance pending with Reprieve. VSR has a patent for treatment of diuretic resistance, US20200079846A1, issued to Yale and Corvidia Therapeutics, with royalties paid to Yale University, VSR and JMT and a patent for measuring renalase WO2019133665A2 issued to Yale. VSR reports personal fees from Translational Catalyst. ZLC reports grants from AstraZeneca. JBIM reports personal fees from Astra-Zeneca, Boehringer Inglheim, Novartis, Merck, Moksha8, and Translational Catalyst. All other authors report no disclosures relevant to the content of this article.